Clinical Trial Update: Phase II Maraviroc for GVHD Prevention [Phase 2]

View source ↗

Summary

A Phase II clinical trial evaluating maraviroc for prevention of graft-versus-host disease (GVHD) in hematologic malignancy patients has completed and posted re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancy

Drugs mentioned

• Maraviroc (maraviroc)

Snippet

Sponsor: Abramson Cancer Center at Penn Medicine | Conditions: Hematologic Malignancy | Phase 2 | Status: COMPLETED | Results posted: 2021-01-11